SCHEMBL3207541

SCHEMBL3207541

CN(C)CC1=CCC(c2ccccc2-c2ccccc2CO)=C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 6/20 0.37
SLC6A2 P23975 3/20 0.36
BACE1 P56817 2/20 0.34
PDCD1 Q15116 1/20 0.33
CD274 Q9NZQ7 1/20 0.33
BRD4 O60885 1/20 0.32
BRD9 Q9H8M2 1/20 0.32
BAZ2B Q9UIF8 1/20 0.32
BAZ2A Q9UIF9 1/20 0.32
DPP4 P27487 1/20 0.32
CYP1A2 P05177 5/20 0.32
CYP3A4 P08684 4/20 0.32
CYP2D6 P10635 4/20 0.32
ALDH1A1 P00352 2/20 0.32
TSHR P16473 2/20 0.32
CYP2C19 P33261 2/20 0.32
CLK4 Q9HAZ1 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.31
ALOX15 P16050 1/20 0.31
LTB4R2 Q9NPC1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3203225 0.94 SLC6A4 (0.39) SLC6A4SLC6A2BACE1PDCD1CD274
SCHEMBL3200656 0.83 KDM4E (0.36) SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6
Hydrochloric Acid SCHEMBL3213185 0.82 CARM1 (0.30)
SCHEMBL3203628 0.78 PDCD1 (0.41) PDCD1CD274BRD4BRD9BAZ2B
Hydrochloric Acid SCHEMBL3213397 0.77 BACE1 (0.33) SLC6A4SLC6A2BACE1CYP1A2CYP3A4
SCHEMBL3213391 0.76 KDM4E (0.46) CYP1A2CYP2D6ALDH1A1CYP2C19
SCHEMBL3201663 0.76 SLC6A4 (0.32) SLC6A4SLC6A2ALDH1A1TSHR
Hydrochloric Acid SCHEMBL3213406 0.76 SLC6A2 (0.31) SLC6A4SLC6A2BACE1ALDH1A1
SCHEMBL3207538 0.75
SCHEMBL6772494 0.75 SLC6A4 (0.49) SLC6A4SLC6A2BACE1PDCD1CD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7732643-B2 Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-06-08 US disclosed
US-7671226-B2 Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-03-02 US disclosed
US-20100048933-A1 TRANSITION METAL COMPLEX, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME HANAOKA HIDENORI 2010-02-25 US disclosed
US-20090054607-A1 Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same HANAOKA HIDENORI 2009-02-26 US disclosed
US-7439379-B2 Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same SUMITOMO CHEMICAL CO., LTD. (JP) 2008-10-21 US disclosed
US-20040242410-A1 Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054607-A1 Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same C1R, C1S, AP1M1 SLC6A4 4222/4885SLC6A2 4524/4885BACE1 1127/4885
US-20100048933-A1 TRANSITION METAL COMPLEX, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME C1R, C1S, AP1M1 SLC6A4 4222/4885SLC6A2 4524/4885BACE1 1127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.